Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04160507 · ClinicalTrials.gov registry record
Duke APOL1 Research Biorepository
A clinical trial of End-Stage Kidney Disease, sponsored by Duke University.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT04160507 is a study of End-Stage Kidney Disease that is actively recruiting participants, run by Duke University. The registered enrollment target is 200 participants, below the 456-participant average among 20 other End-Stage Kidney Disease trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04160507, a study of End-Stage Kidney Disease, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The Duke ApoL1 Nephropathy Biorepository aims to address needs within non-diabetic kidney failure research by utilizing existing and, when necessary, developing new infrastructure to support the consent of patients and the collection of dedicated samples for ApoL1 Nephropathy biorepository. The mutations in ApoL1 gene that are strongly associated with kidney disease are only present in individuals of recent African ancestry (i.e., black people). Caucasians do not have these ApoL1 mutations nor the associated kidney disease. Therefore, majority of subjects recruited for this study will be self-identified African Americans, Afro-Caribbean and other black individual. Study subjects will include individuals with end stage kidney disease and those without any clinical evidence of kidney disease. Additionally, healthy black adults with no known history of kidney disease will be recruited as controls in this study because they are the only group that can fill this role.
Conditions Studied
Interventions
- OTHER Biorepository
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2019-12-13 |
| Est. Completion | 2026-11-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04160507
The ClinicalTrials.gov registry entry for NCT04160507 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 456-participant average among 20 other End-Stage Kidney Disease trials with a reported enrollment target (56% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with End-Stage Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Biorepository is the first listed.
NCT04160507 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04160507 about?
NCT04160507 is a clinical study titled "Duke APOL1 Research Biorepository". The Duke ApoL1 Nephropathy Biorepository aims to address needs within non-diabetic kidney failure research by utilizing existing and, when necessary, developing new infrastructure to support the consent of patients and the collection of dedicated samples for ApoL1 Nephropathy biorepository. The mut...
What is the current status of trial NCT04160507?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2019-12-13. Estimated completion is 2026-11-15.
What conditions does trial NCT04160507 study?
This clinical trial studies the following conditions: End-Stage Kidney Disease.
What interventions are being tested in trial NCT04160507?
The interventions under investigation include: Biorepository (OTHER).
Who is sponsoring clinical trial NCT04160507?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04160507 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End-Stage Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Incremental Hemodialysis: The TwoPlus Trial
RECRUITING · NA
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
RECRUITING · Phase 3
-
Symptom Monitoring in Hemodialysis
RECRUITING · NA
-
Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants
RECRUITING · NA
-
Pain Reduction Using NEurostimulation Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.